Abstract
Introduction Diabetes insipidus (DI) is characterized by the excretion of large volumes of hypotonic urine and thirst due to an impaired ability to concentrate urine, leading to uncontrolled diuresis, which may cause life-threatening dehydration and electrolyte imbalances. Central DI is caused by the deficient secretion of the posterior pituitary antidiuretic hormone arginine vasopressin (AVP). Desmopressin (Deamino-8-D-AVP, the synthetic analogue of AVP, Minirinmelt®) is generally used to treat central DI. Desmopressin orally disintegrating tablets are recently administered to male patients with nocturia. We herein attempted to select male patients with an elevated nocturnal urinary frequency possibly due to a shortage of AVP. These patients may be good candidates for low-dose oral desmopressin administration.
Patients and methods Serum and spot urine osmolality, electrolytes, serum creatinine, casual blood glucose, plasma brain natriuretic polypeptide (BNP), and plasma AVP were measured at the same time in 97 elderly male patients with urinary symptoms under free water drinking. The International Prostate Symptom Score, Overactive Bladder Symptom Score, and frequency-volume charts at least twice were also evaluated.
Results A binary plot of plasma AVP and serum osmolality indicated a region at which patients had relatively lower AVP considering higher serum osmolality. It was tentatively named the Desmopressin region. Twenty out of 97 (20.6 %) patients were in the Desmopressin region.
No significant differences were observed in the frequency of administered urinary drugs or existing co-morbidities between patients in the Desmopressin and non-Desmopressin regions. Daily urine output did not exceed 3 L in any patient. Plasma AVP was lower, while serum osmolality and serum sodium were higher in patients in the Desmopressin region than in those in non-Desmopressin region. Furthermore, urine osmolality was slightly lower in patients in the Desmopressin region. No significant differences were observed in urine volume, urinary frequency, or urination questionnaire scores between both groups.
Conclusion AVP-shortage patients may be selected for treatment with oral desmopressin based on measurements of serum osmolality and plasma AVP. After the exclusion of patients with marked hyperglycemia, decreased cardiac, or renal function, low-dose oral desmopressin may be administered to patients with an increased urine output, nocturia, elevated plasma osmolality, and relatively low plasma AVP.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
It is a retrospective study.
Funding Statement
There is no funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was conducted in accordance with the Helsinki Declaration after approval of the Ethics Committee of Kanto Rosai Hospital (G2020-3).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Not available
